Document Detail


Sublingual versus vaginal misoprostol (400 microg) for cervical priming in first-trimester abortion: a randomized trial.
MedLine Citation:
PMID:  16982235     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Our objective was to compare the sublingual administration and the vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion. DESIGN: We used an open, multicenter, randomized trial. LOCATIONS: We conducted the study in four clinics (in Valencia, Castelló, Murcia and Murcia Capital) in Spain. PARTICIPANTS: A total of 1424 healthy pregnant women with amenorrhea of <or=84 days who voluntarily decided to terminate their pregnancy participated in the study. METHODS: Women were randomly assigned to receive a single dose of 400 microg of misoprostol either sublingually or vaginally 1-3 h before aspiration. OUTCOME MEASURES: The outcome measures assessed were cervical dilation before surgery and surgical time needed for aspiration. The incidence of side effects, such as nausea, vomiting, diarrhea, fever/chills and paresthesia, was evaluated. RESULTS: The mean cervical dilation achieved was 6.8+/-0.8 and 6.7+/-0.9 mm for the sublingual and vaginal groups, respectively. The mean surgical time was 7.0+/-2.8 and 7.4+/-2.5 min for the sublingual and vaginal groups, respectively. Nausea, vomiting and diarrhea were more frequent in the sublingual group. CONCLUSIONS: Both regimens had equal efficacy; however, the sublingual route caused more side effects.
Authors:
Josep Lluis Carbonell Esteve; Jose Maria Marí; Francisco Valero; Margardel Llorente; Immaculada Salvador; Lidia Varela; Pedro Leal; Ana Candel; Ana Tudela; Maria Serrano; Eva Muñoz
Related Documents :
12814815 - Mifepristone and misoprostol for early medical abortion: 18 months experience in the un...
15722075 - Failed medical termination of twin pregnancy with mifepristone: a case report.
15516385 - Trends in congenital malformations, 1974-1999: effect of prenatal diagnosis and electiv...
15125405 - Prenatal testing and pregnancy termination in sri lanka: views of medical students and ...
6161585 - Separation of two pregnancy-associated proteins with sp1 determinants and the conversio...
7102575 - Localization of relaxin in endometrial gland cells of pregnant, lactating, and ovariect...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2006-05-23
Journal Detail:
Title:  Contraception     Volume:  74     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-19     Completed Date:  2007-02-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  United States    
Other Details:
Languages:  eng     Pagination:  328-33     Citation Subset:  IM    
Affiliation:
Clínica Mediterrania Médica, Valencia 46017, Castelló, Spain. schja@infomed.sld.cu <schja@infomed.sld.cu>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Nonsteroidal / administration & dosage,  adverse effects
Abortion, Induced / methods*
Administration, Intravaginal
Administration, Sublingual
Adult
Cervical Ripening / drug effects*
Drug Administration Routes
Female
Humans
Misoprostol / administration & dosage*,  adverse effects
Pregnancy
Pregnancy Trimester, First / drug effects*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 59122-46-2/Misoprostol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The use of vaginal misoprostol for second-trimester pregnancy termination in women with previous sin...
Next Document:  Timing of steps and reasons for delays in obtaining abortions in the United States.